Reviewed by Michael Gill, B. Sc.
25 Chronic Kidney Disease Clinical Trials Near Me
Top Hospitals for Chronic Kidney Disease Clinical Trials
Image of Clinical Advancement Center, PLLC in Texas.
Clinical Advancement Center, PLLC
San Antonio
5Active Trials
0All Time Trials for Chronic Kidney Disease
2021First Chronic Kidney Disease Trial
Image of Southeast Renal Research Institute in Tennessee.
Southeast Renal Research Institute
Chattanooga
3Active Trials
0All Time Trials for Chronic Kidney Disease
2012First Chronic Kidney Disease Trial
Top Cities for Chronic Kidney Disease Clinical Trials
Chronic Kidney Disease Clinical Trials by Phase of Trial
Phase 1 Chronic Kidney Disease Clinical Trials
6Active Chronic Kidney Disease Clinical Trials
6Number of Unique Treatments
10Number of Active Locations
Conditioning and Stem cell infusionCLBS201Alkalizing Fruit and VegetablesAllogeneic adipose-derived mesenchymal stem cells (MSC)-Single InfusionAllogeneic adipose-derived mesenchymal stem cells (MSC)REACT - renal autologous cell therapy
Chronic Kidney Disease Clinical Trials by Age Group
< 18 Chronic Kidney Disease Clinical Trials
5Active Chronic Kidney Disease Clinical Trials
TrifericParicalcitolFerumoxytolFinerenone (Kerendia, BAY94-8862)Ferric Citrate
Most Recent Chronic Kidney Disease Clinical Trials
Top Treatments for Chronic Kidney Disease Clinical Trials
Treatment Name
Active Chronic Kidney Disease Clinical Trials
All Time Trials for Chronic Kidney Disease
First Recorded Chronic Kidney Disease Trial
Renal Autologous Cell Therapy (REACT®)
3
3
2016
Finerenone (Kerendia, BAY94-8862)
2
2
2022
Difelikefalin 1 mg Oral Tablet
2
2
2022
Semaglutide
2
2
2019
MitoQ
2
2
2017

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 15th, 2021

Last Reviewed: November 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. https://pubmed.ncbi.nlm.nih.gov/115569412 Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. https://pubmed.ncbi.nlm.nih.gov/167171713 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. https://pubmed.ncbi.nlm.nih.gov/35587164 Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2:CD008834. doi: 10.1002/14651858.CD008834.pub4. Review. https://pubmed.ncbi.nlm.nih.gov/352247305 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. https://pubmed.ncbi.nlm.nih.gov/35587166 Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9. https://pubmed.ncbi.nlm.nih.gov/154643187 Kim J, Shin W. How to do random allocation (randomization). Clin Orthop Surg. 2014 Mar;6(1):103-9. doi: 10.4055/cios.2014.6.1.103. Epub 2014 Feb 14. https://pubmed.ncbi.nlm.nih.gov/246051978 King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172. https://pubmed.ncbi.nlm.nih.gov/248363129 Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, Budaj A, Niemelä M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR; RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011 Apr 23;377(9775):1409-20. doi: 10.1016/S0140-6736(11)60404-2. Epub 2011 Apr 4. Erratum in: Lancet. 2011 Apr 23;377(9775):1408. Lancet. 2011 Jul 2;378(9785):30. https://pubmed.ncbi.nlm.nih.gov/2147067110 Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, Budaj A, Niemelä M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR; RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011 Apr 23;377(9775):1409-20. doi: 10.1016/S0140-6736(11)60404-2. Epub 2011 Apr 4. Erratum in: Lancet. 2011 Apr 23;377(9775):1408. Lancet. 2011 Jul 2;378(9785):30. https://pubmed.ncbi.nlm.nih.gov/21470671